Suchen
Innate Pharma SA
IPHAZur Watchlist hinzufügen
2.180USD
-0.355-14.00%
Handelsschluss 08-14 16:00（ET）Kurse um 15 Minuten verzögert
202.21MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Innate Pharma SA Unternehmen
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.
Innate Pharma SA Profil
BörsenkürzelIPHA
Name des UnternehmensInnate Pharma SA
IPO-datumOct 31, 2006
CEODickinson (Jonathan Elliot)
Anzahl der mitarbeiter181
WertpapierartDepository Receipt
GeschäftsjahresendeOct 31
Addresse117 avenue de Luminy
StadtMARSEILLE
BörseNASDAQ OMX - NASDAQ BASIC
LandFrance
Postleitzahl13009
Telefon33430303030
Websitehttps://www.innate-pharma.com/
BörsenkürzelIPHA
IPO-datumOct 31, 2006
CEODickinson (Jonathan Elliot)
Führungskräfte von Innate Pharma SA
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Gilles Brisson
Mr. Gilles Brisson
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Mrs. Irina Staatz-Granzer, Ph.D.
Mrs. Irina Staatz-Granzer, Ph.D.
Chairwoman of the Board of Directors
Chairwoman of the Board of Directors
--
--
Mr. Yannis Morel, Ph.D.
Mr. Yannis Morel, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Ms. Veronique Chabernaud, M.D.
Ms. Veronique Chabernaud, M.D.
Independent Director
Independent Director
--
--
Prof. Eric Vivier, Ph.D.
Prof. Eric Vivier, Ph.D.
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
--
--
Prof. Jean-Yves Blay, Ph.D.
Prof. Jean-Yves Blay, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Ms. Odile Belzunce
Ms. Odile Belzunce
Chief Compliance and Operations Officer, Interim Head of human Resources, Vice President
Chief Compliance and Operations Officer, Interim Head of human Resources, Vice President
--
--
Ms. Odile Laurent
Ms. Odile Laurent
Vice President - Human Resources, Member of the Leadership Team
Vice President - Human Resources, Member of the Leadership Team
--
--
Ms. Pascale Boissel
Ms. Pascale Boissel
Vice Independent Chairman of the Board
Vice Independent Chairman of the Board
--
--
Mr. Olivier Martinez
Mr. Olivier Martinez
Independent Director, Representative of Bpifrance Participations
Independent Director, Representative of Bpifrance Participations
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Gilles Brisson
Mr. Gilles Brisson
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Mrs. Irina Staatz-Granzer, Ph.D.
Mrs. Irina Staatz-Granzer, Ph.D.
Chairwoman of the Board of Directors
Chairwoman of the Board of Directors
--
--
Mr. Yannis Morel, Ph.D.
Mr. Yannis Morel, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Ms. Veronique Chabernaud, M.D.
Ms. Veronique Chabernaud, M.D.
Independent Director
Independent Director
--
--
Prof. Eric Vivier, Ph.D.
Prof. Eric Vivier, Ph.D.
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
--
--
Prof. Jean-Yves Blay, Ph.D.
Prof. Jean-Yves Blay, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Innate Pharma SA?
Die fünf größten Anteilseigner von Innate Pharma SA sind: Mr. Gilles Brisson
Wie viele Institutionen halten Anteile an Innate Pharma SA (IPHA)?
Mit Stand vom 2026Q1 halten 22 Institutionen Anteile an Innate Pharma SA, mit einem Gesamtmarktwert von etwa 336.10K, was 0.37% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 136136.00 gestiegen.